Leerink Partners Maintains Outperform on Sutro Biopharma, Raises Price Target to $43

Benzinga Newsdesk www.benzinga.com Positive 93.1%

Neg 0% Neu 0% Pos 93.1%

Leerink Partners maintains Sutro Biopharma (NASDAQ:STRO) with a Outperform and raises the price target from $38 to $43.

Comments

No comments yet. Be the first!